Back to Search Start Over

FLASH X-ray spares intestinal crypts from pyroptosis initiated by cGAS-STING activation upon radioimmunotherapy

Authors :
Xiaolin Shi
Yiwei Yang
Wei Zhang
Jianxin Wang
Dexin Xiao
Huangge Ren
Tingting Wang
Feng Gao
Zhen Liu
Kui Zhou
Peng Li
Zheng Zhou
Peng Zhang
Xuming Shen
Yu Liu
Jianheng Zhao
Zhongmin Wang
Fenju Liu
Chunlin Shao
Dai Wu
Haowen Zhang
Source :
Proceedings of the National Academy of Sciences of the United States of America. 119(43)
Publication Year :
2023

Abstract

DNA-damaging treatments such as radiotherapy (RT) have become promising to improve the efficacy of immune checkpoint inhibitors by enhancing tumor immunogenicity. However, accompanying treatment-related detrimental events in normal tissues have posed a major obstacle to radioimmunotherapy and present new challenges to the dose delivery mode of clinical RT. In the present study, ultrahigh dose rate FLASH X-ray irradiation was applied to counteract the intestinal toxicity in the radioimmunotherapy. In the context of programmed cell death ligand-1 (PD-L1) blockade, FLASH X-ray minimized mouse enteritis by alleviating CD8 + T cell-mediated deleterious immune response compared with conventional dose rate (CONV) irradiation. Mechanistically, FLASH irradiation was less efficient than CONV X-ray in eliciting cytoplasmic double-stranded DNA (dsDNA) and in activating cyclic GMP-AMP synthase (cGAS) in the intestinal crypts, resulting in the suppression of the cascade feedback consisting of CD8 + T cell chemotaxis and gasdermin E-mediated intestinal pyroptosis in the case of PD-L1 blocking. Meanwhile, FLASH X-ray was as competent as CONV RT in boosting the antitumor immune response initiated by cGAS activation and achieved equal tumor control in metastasis burdens when combined with anti–PD-L1 administration. Together, the present study revealed an encouraging protective effect of FLASH X-ray upon the normal tissue without compromising the systemic antitumor response when combined with immunological checkpoint inhibitors, providing the rationale for testing this combination as a clinical application in radioimmunotherapy.

Details

ISSN :
10916490
Volume :
119
Issue :
43
Database :
OpenAIRE
Journal :
Proceedings of the National Academy of Sciences of the United States of America
Accession number :
edsair.doi.dedup.....92dd42ab80ce95568864e9bafef6d061